Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Randomized Controlled Trial
100%
Prognostic Biomarker
100%
Tocilizumab
100%
COVID-19
100%
Placebo
71%
Clinical Outcomes
57%
Clinical Status
42%
Mechanical Ventilation
42%
Ferritin
42%
Coronavirus Disease 2019 Pneumonia
42%
Hospital Discharge
28%
D-dimer
28%
Lactate Dehydrogenase
28%
Severe Coronavirus Disease 2019
28%
C-reactive Protein
14%
Interleukin-6
14%
Patient Demographics
14%
Placebo-controlled
14%
Monocytes
14%
Randomized Double-blind
14%
Predictive Value
14%
Sensitivity Analysis
14%
North America
14%
North Europe
14%
Lymphocytes
14%
Platelets
14%
Neutrophils
14%
Multiple Biomarkers
14%
Retrospective Observational Study
14%
Ordinal Scale
14%
Clinical Time
14%
Fine-Gray Model
14%
Interleukin-6 Inhibitors
14%
Ferritin Levels
14%
Proportional Odds
14%
Control Phase
14%
Phase 3 Trial
14%
Efficacy Outcomes
14%
Medicine and Dentistry
Randomized Controlled Trial
100%
Biological Marker
100%
Tocilizumab
100%
COVID-19
100%
Placebo
85%
Arm
57%
Ferritin
57%
Artificial Respiration
42%
Pneumonia
42%
D-Dimer
28%
Lactate Dehydrogenase
28%
C Reactive Protein
14%
Patient Population
14%
Interleukin 6
14%
Observational Study
14%
Platelet
14%
Receptor Antibody
14%
Interleukin 6 Receptor
14%
Lymphocyte
14%
Neutrophil
14%
Monocyte
14%
Immunology and Microbiology
Tocilizumab
100%
COVID-19
100%
Arm
57%
Ferritin
57%
Lactic Acid
28%
C-Reactive Protein
14%
Monocyte
14%
Platelet
14%
Neutrophil
14%
Interleukin 6
14%
Interleukin-6 Receptor
14%
Prognostic Biomarker
14%
Receptor Antibody
14%
Lymphocyte
14%
Lactate
14%